Search

Your search keyword '"Fukushima, Atsuki"' showing total 668 results
Start Over Author "Fukushima, Atsuki"
668 results on '"Fukushima, Atsuki"'

106. The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway

Author

Sakamoto, Shuji, Aoki, Kazuma, Higuchi, Takuma, Todaka, Hiroshi, Morisawa, Keiko, Tamaki, Nobuyuki, Hatano, Etsuro, Fukushima, Atsuki, Taniguchi, Taketoshi, Agata, Yasutoshi, Sakamoto, Shuji, Aoki, Kazuma, Higuchi, Takuma, Todaka, Hiroshi, Morisawa, Keiko, Tamaki, Nobuyuki, Hatano, Etsuro, Fukushima, Atsuki, Taniguchi, Taketoshi, and Agata, Yasutoshi

Published
2018

107. Requirement of longer term antiviral therapy in patients with cytomegalovirus anterior uveitis with corneal endothelial cell damage

Author

Harada,Yosuke, Fukuda,Ken, Nakahira,Asami, Tada,Kentaro, Sumi,Tamaki, Fukushima,Atsuki, Harada,Yosuke, Fukuda,Ken, Nakahira,Asami, Tada,Kentaro, Sumi,Tamaki, and Fukushima,Atsuki

Abstract

Yosuke Harada,1,2 Ken Fukuda,1 Asami Nakahira,1 Kentaro Tada,1 Tamaki Sumi,1 Atsuki Fukushima1 1Department of Ophthalmology and Visual Science, Kochi Medical School, Nankoku, Japan; 2Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan Background: The aim of the study was to investigate the efficacy of therapy in patients with cytomegalovirus (CMV) anterior uveitis. Patients and methods: We reviewed the records of patients with CMV anterior uveitis who attended our institution between October 2010 and December 2015 and who were confirmed to have CMV DNA in the aqueous humor by polymerase chain reaction analysis. Results: Fourteen immunocompetent patients (10 men and 4 women, total of 17 eyes) were enrolled. The mean ± SD age at the onset of antiviral therapy was 63.1 ± 11.3 years (range, 44–87 years). CMV DNA was not detected in the aqueous humor of 3 patients on initial testing, but it was detected on subsequent analysis. All patients underwent systemic antiviral therapy. Among the patients who were followed up for more than 6 months after starting systemic antiviral therapy, systemic antiviral therapy was successfully terminated in all 4 patients without corneal endothelial loss but had to be continued because of disease recurrence on its termination in 5 of 8 patients (62.5%) with corneal endothelial damage (P = 0.038). Conclusions: Patients with corneal endothelial cell loss are likely to require longer term antiviral therapy than those without endothelial damage. In addition, whereas definitive diagnosis of CMV anterior uveitis requires the detection of CMV DNA in aqueous humor by polymerase chain reaction, one-fifth of patients in the present study tested negative on initial examination. Keywords: cytomegalovirus, anterior uveitis, corneal endothelial cell, polymerase chain reaction, clinical course

Published
2018

116. Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular Diseases

Author

Miyazaki, Dai, primary, Fukushima, Atsuki, additional, Ohashi, Yuichi, additional, Ebihara, Nobuyuki, additional, Uchio, Eiichi, additional, Okamoto, Shigeki, additional, Shoji, Jun, additional, Takamura, Etsuko, additional, Nakagawa, Yayoi, additional, Namba, Kenichi, additional, and Fujishima, Hiroshi, additional

Published
2017
Full Text
View/download PDF

120. Hyperemia Analysis Software for Assessment of Conjunctival Hyperemia Severity.

Author

Yoneda, Tsuyoshi, Sumi, Tamaki, Hoshikawa, Yasuhiro, Kobayashi, Masahiko, and Fukushima, Atsuki

Subjects
HYPEREMIA, BLOOD vessels, COMPUTER software, IMAGE processing, ALLERGIES, CONJUNCTIVA
Abstract

Purpose: We developed a hyperemia analysis software, which can quantitatively assess the degree of conjunctival hyperemia, and evaluated the reproducibility and reliability of its percent coverage. In addition, we compared the clinical grading and the percent coverage to examine the applicability of the software analysis. Methods: We took images of the temporal conjunctiva with slit lamp microscopes. We used our hyperemia analysis software to detect blood vessels in the region of interest using its image processing capabilities and obtained a ratio of the area occupied by blood vessels to the rest of the area. In addition, we used the clinical evaluation criteria of the Japanese guidelines for allergic conjunctival diseases 2017 to clinically grade the hyperemia in each eye. Nine evaluators examined the images and graded the severity of hyperemia into four stages. We looked for a statistical correlation between the results of the hyperemia analysis software and the clinical grading. Results: The percent coverage of the blood vessels in the region of interest calculated by the hyperemia analysis software correlated with the arithmetic average of our clinical grading (r = 0.953; 95% CI, 0.8470340–0.9862136). Conclusion: The percent coverage from our hyperemia analysis software reflects the clinical grading score, suggesting that our software can be used to obtain a detailed analysis of conjunctival hyperemia. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

122. Miscellaneous Ocular Symptoms in a Case of Relapsing Polychondritis.

Author

Fukuda, Ken, Kishimoto, Tatsuma, and Fukushima, Atsuki

Subjects
HEARING disorders, COLOR Doppler ultrasonography, EYE movement disorders, SYMPTOMS, POSITRON emission tomography, MOVEMENT disorders
Abstract

Purpose: To report a case of miscellaneous ocular symptoms associated with relapsing polychondritis (RP).Case Report: A 58-year-old man presented with multiple ocular symptoms including both anterior and posterior scleritis, conjunctivitis, eyelid edema, eye movement disorder, keratitis, and retinopathy. Miscellaneous systemic inflammation in the right auricle as well as nasal and laryngeal cartilage was also evident together with vestibular and auditory nerve disorders. According to his clinical signs and the results of color Doppler ultrasonography, positron emission tomography and computed tomography, and a biopsy of the right auricle, we made a diagnosis of RP.Conclusion: Given that RP is potentially fatal, it is important that the condition be diagnosed early and treated promptly. Ophthalmologists should be aware that RP is a potential cause of recurrent and refractory multiple ocular inflammatory disorders associated with systemic symptoms. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

123. Use of Explainable AI on Slit-lamp Images of Anterior Surface of eyes to Diagnose Allergic Conjunctival Diseases

Author

Yonehara, Michiko, Nakagawa, Yuji, Ayatsuka, Yuji, Hara, Yuko, Shoji, Jun, Ebihara, Nobuyuki, Inomata, Takenori, Huang, Tianxiang, Nagino, Ken, Fukuda, Ken, Kishimoto, Tatsuma, Sumi, Tamaki, Fukushima, Atsuki, Fujishima, Hiroshi, Kawai, Moeko, Takamura, Etsuko, Uchio, Eiichi, Namba, Kenichi, Koyama, Ayumi, Haruki, Tomoko, Sasaki, Shin-ich, Shimizu, Yumiko, and Miyazaki, Dai

Abstract

Artificial intelligence (AI) is a promising new technologythat has the potential of diagnosingallergic conjunctival diseases (ACDs). However, its development is slowed by the absence of a tailored image database and explainable AI models. Thus, the purpose of this study was to develop an explainable AI model that can not only diagnose ACDs but also present the basis for the diagnosis.

Published
2024
Full Text
View/download PDF

124. Japanese guidelines for allergic conjunctival diseases 2017

Author

Takamura, Etsuko, Uchio, Eiichi, Ebihara, Nobuyuki, Ohno, Shigeaki, Ohashi, Yuichi, Okamoto, Shigeki, Kumagai, Naoki, Satake, Yoshiyuki, Shoji, Jun, Nakagawa, Yayoi, Namba, Kenichi, Fukagawa, Kazumi, Fukushima, Atsuki, and Fujishima, Hiroshi

Abstract

The definition, classification, pathogenesis, test methods, clinical findings, criteria for diagnosis, and therapies of allergic conjunctival disease are summarized based on the Guidelines for Clinical Management of Allergic Conjunctival Disease (Second Edition) revised in 2010. Allergic conjunctival disease is defined as “a conjunctival inflammatory disease associated with a Type I allergy accompanied by some subjective or objective symptoms.” Allergic conjunctival disease is classified into allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. Representative subjective symptoms include ocular itching, hyperemia, and lacrimation, whereas objective symptoms include conjunctival hyperemia, swelling, folliculosis, and papillae. Patients with vernal keratoconjunctivitis, which is characterized by conjunctival proliferative changes called giant papilla accompanied by varying extents of corneal lesion, such as corneal erosion and shield ulcer, complain of foreign body sensation, ocular pain, and photophobia. In the diagnosis of allergic conjunctival diseases, it is required that type I allergic diathesis is present, along with subjective and objective symptoms accompanying allergic inflammation. The diagnosis is ensured by proving a type I allergic reaction in the conjunctiva. Given that the first-line drug for the treatment of allergic conjunctival disease is an antiallergic eye drop, a steroid eye drop will be selected in accordance with the severity. In the treatment of vernal keratoconjunctivitis, an immunosuppressive eye drop will be concomitantly used with the abovementioned drugs.

Published
2024
Full Text
View/download PDF

127. Roles of Epithelial Cell–Derived Type 2–Initiating Cytokines in Experimental Allergic Conjunctivitis

Author

Asada, Yosuke, primary, Nakae, Susumu, additional, Ishida, Waka, additional, Hori, Kanji, additional, Sugita, Jobu, additional, Sudo, Katsuko, additional, Fukuda, Ken, additional, Fukushima, Atsuki, additional, Suto, Hajime, additional, Murakami, Akira, additional, Saito, Hirohisa, additional, Ebihara, Nobuyuki, additional, and Matsuda, Akira, additional

Published
2015
Full Text
View/download PDF

128. Overexpression of NF90-NF45 Represses Myogenic MicroRNA Biogenesis, Resulting in Development of Skeletal Muscle Atrophy and Centronuclear Muscle Fibers

Author

Todaka, Hiroshi, primary, Higuchi, Takuma, additional, Yagyu, Ken-ichi, additional, Sugiyama, Yasunori, additional, Yamaguchi, Fumika, additional, Morisawa, Keiko, additional, Ono, Masafumi, additional, Fukushima, Atsuki, additional, Tsuda, Masayuki, additional, Taniguchi, Taketoshi, additional, and Sakamoto, Shuji, additional

Published
2015
Full Text
View/download PDF

132. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4%.

Author

Terao, Etsuko, Nakakura, Shunsuke, Fujisawa, Yasuko, Fujio, Yuki, Matsuya, Kanae, Kobayashi, Yui, Tabuchi, Hitoshi, Yoneda, Tsuyoshi, Fukushima, Atsuki, and Kiuchi, Yoshiaki

Subjects
EYE drops, RHO-associated kinases, HYPEREMIA, GLAUCOMA treatment, CONJUNCTIVA diseases, KINASE inhibitors, THERAPEUTICS
Abstract

Purpose: We investigated the detailed time course of conjunctival hyperemia induced by ripasudil 0.4%, a novel Rho-kinase inhibitor anti-glaucoma eye drop, in healthy subjects. Methods: We recruited 51 healthy subjects and administered ripasudil 0.4% in their right eye. We evaluated conjunctival hyperemia using slit lamp photography and measured the intraocular pressure (IOP) using the Icare PRO Rebound Tonometer at baseline and after 5, 15, 30, 60, 90, and 120 min. The conjunctival hyperemia score was graded by three independent observers on a scale of 0 (none) to 3 (severe). Additionally, we analyzed the “percent coverage” of conjunctival hyperemia by using an automated hyperemia analysis software program; this program provides the pixel coverage of the conjunctival vessels in the region of interest. Dunnett and Steel multiple comparison tests were used, as appropriate, for the subsequent analyses. Results: The conjunctival hyperemia score and percent coverage increased rapidly after the instillation of ripasudil 0.4%, peaking at 15 min (score: 1.83 ± 0.29 [mean ± SD]) and 5 min (11.6% ± 4.7%), respectively, and then gradually decreasing until 120 min (0.45 ± 0.22 and 4.7% ± 1.8%, respectively), when they reached a level that was not significantly different from the baseline values. The IOP decreased significantly compared to the baseline at 30, 60, and 90 min, based on the Dunnett test. Conclusion: Conjunctival hyperemia induced by ripasudil 0.4% peaks rapidly to moderate severity, but subsides relatively quickly. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

134. Case of cytomegalovirus retinitis aggravated by sub-Tenon injection of triamcinolone acetonide with subsequent metastatic liver cancer

Author

Yamamoto,Yumiko, Kato,Yoshitake, Tabuchi,Hitoshi, Fukushima,Atsuki, Yamamoto,Yumiko, Kato,Yoshitake, Tabuchi,Hitoshi, and Fukushima,Atsuki

Abstract

Yumiko Yamamoto,1 Yoshitake Kato,2 Hitoshi Tabuchi,2 Atsuki Fukushima11Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi, Japan; 2Department of Ophthalmology, Tsukazaki Hospital, Hyogo, JapanAbstract: We report a case of cytomegalovirus (CMV) retinitis in an immunocompetent patient who was resistant to antiviral treatment, and in whom fatal metastatic liver cancer was later detected. A 74-year-old Japanese man visited our ophthalmology clinic in May 2011. He had a history of well controlled type 2 diabetes and colon cancer, and underwent successful surgical treatment in 2008. In April 2011, he was diagnosed with uveitis affecting his left eye and received posterior sub-Tenon injection of triamcinolone acetonide. He was referred to us because of aggravation of the retinal lesion. Funduscopic examination of the left eye revealed arcuate, whitish, necrotizing retinitis with hemorrhage along the temporal arcade of the retina. Polymerase chain reaction of the aqueous fluid was positive for CMV DNA. Because of diagnosis of CMV retinitis in his left eye, he was referred to an internist and investigated for systemic CMV infection or any serious disease which could cause immunocompromise, but neither was detected. Despite an intensive course of intravitreous ganciclovir and oral valganciclovir, the retinitis did not resolve. In June 2012, 14 months after the initial ocular symptoms, metastatic liver cancer was found and the patient passed away. When CMV retinitis is resistant to antiviral treatment or recurs in an immunocompetent patient, it is important that ophthalmologists undertake systemic investigation for occult malignancy.Keywords: cytomegalovirus, retinitis, uveitis, immunocompromised, immunocompetent, triamcinolone acetonide, diabetes, ganciclovir, valganciclovir

Published
2013

141. High Expression of Nuclear Factor 90 (NF90) Leads to Mitochondrial Degradation in Skeletal and Cardiac Muscles

Author

Higuchi, Takuma, primary, Sakamoto, Shuji, additional, Kakinuma, Yoshihiko, additional, Kai, Shoko, additional, Yagyu, Ken-ichi, additional, Todaka, Hiroshi, additional, Chi, Eunsup, additional, Okada, Shoshiro, additional, Ujihara, Takako, additional, Morisawa, Keiko, additional, Ono, Masafumi, additional, Sugiyama, Yasunori, additional, Ishida, Waka, additional, Fukushima, Atsuki, additional, Tsuda, Masayuki, additional, Agata, Yasutoshi, additional, and Taniguchi, Taketoshi, additional

Published
2012
Full Text
View/download PDF

146. Japanese Guideline for Allergic Conjunctival Diseases

Author

Takamura, Etsuko, primary, Uchio, Eiichi, additional, Ebihara, Nobuyuki, additional, Ohno, Shigeaki, additional, Ohashi, Yuichi, additional, Okamoto, Shigeki, additional, Kumagai, Naoki, additional, Satake, Yoshiyuki, additional, Shoji, Jun, additional, Nakagawa, Yayoi, additional, Namba, Kenichi, additional, Fukagawa, Kazumi, additional, Fukushima, Atsuki, additional, and Fujishima, Hiroshi, additional

Published
2011
Full Text
View/download PDF

148. Inhibition by Tranilast of the Synergistic Induction of Degranulation and IL-13 Expression by IL-33 and FcɛRI Cross-linking in Mast Cells.

Author

Tsuji, Kazuhiro, Fukuda, Ken, and Fukushima, Atsuki

Subjects
MAST cells, INTERLEUKIN-13, IMMUNOGLOBULIN E, HEXOSAMINIDASE, MESSENGER RNA
Abstract

Purpose: To assess the effects of tranilast on degranulation and IL-13 production in mast cells activated by IL-33 and cross-linking of FcɛRI.Methods: Bone marrow-derived mast cells (BMMCs) were sensitized with anti-DNP IgE. Sensitized cells were pretreated with tranilast and further stimulated with DNP-BSA, IL-33, or a combination of DNP-BSA and IL-33. Degranulation and the level of IL-13 release and mRNA expression in BMMCs were measured.Results: Simultaneous stimulation with DNP-BSA and IL-33 resulted in marked increase in β-hexosaminidase release. Tranilast significantly inhibited degranulation of BMMCs in the condition of combined treatment of DNP-BSA and IL-33. Combination of DNP-BSA and IL-33 induced a pronounced increase in the IL-13 release and mRNA expression. Tranilast significantly inhibited IL-13 release and mRNA expression in BMMCs stimulated by DNP-BSA and IL-33.Conclusions: Tranilast has efficacy on the inhibition of degranulation and IL-13 production in BMMCs induced by the combination of DNP-BSA and IL-33. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

150. A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis

Author

Ohashi, Yuichi, primary, Ebihara, Nobuyuki, additional, Fujishima, Hiroshi, additional, Fukushima, Atsuki, additional, Kumagai, Naoki, additional, Nakagawa, Yayoi, additional, Namba, Kenichi, additional, Okamoto, Shigeki, additional, Shoji, Jun, additional, Takamura, Etsuko, additional, and Hayashi, Kunihiko, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results